{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:34Z","timestamp":1790983114325,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Widespread application of immune checkpoint inhibitors (ICIs) has led to a noticeable increase in patients developing the triad of severe myasthenia gravis (MG), myocarditis, and myositis. However, this overlapping triad syndrome is still very rare, characterized by a subtle onset, a rapid progression, and a high mortality rate. Due to its insidious onset and diagnostic challenges, there is currently limited knowledge of this overlapping triad syndrome in clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of a male colon cancer patient with suspected thymic metastasis who developed the overlapping immune-related myocarditis, myositis, and MG-like symptoms after one cycle of ICI treatment. The patient received timely administration of corticosteroids, oxygen therapy, immunoglobulin, and other treatments, following which he recovered and was discharged. No discernible adverse impact on his subsequent quality of life was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vigilance is warranted for the risk of developing a triad of severe MG, myocarditis, and myositis when patients receiving ICIs present with symptoms such as exertional dyspnea, swallowing weakness, diplopia, dysarthria, limb weakness, or inability to walk due to muscle pain, particularly for patients with thymic masses. Such patients should be monitored in the hospital and, if necessary, admitted to the intensive care unit, where they will be managed by a multidisciplinary team of specialists.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1808170","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:20:43Z","timestamp":1786422043000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Immune checkpoint inhibitor-induced myositis\/myocarditis with myasthenia gravis-like symptoms in a colon cancer patient with suspected thymic metastasis"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Lun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Hua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Juan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Qi","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Na","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Lun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Juan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Affiliated Hospital of Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018","volume":"320","author":"Johnson","year":"2018","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2024.2351519","article-title":"Checkpoint inhibitor-related myasthenia-myocarditis-myositis overlap syndrome in the orbit","volume":"44","author":"Park","year":"2025","journal-title":"Orbit (Amsterdam Netherlands)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Network"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1801-23","article-title":"Liver cancer with overlapping myasthenia gravis, myocarditis, seronegative autoimmune autonomic ganglionopathy, and myositis symptoms induced by atezolizumab","volume":"63","author":"Shibuya","year":"2024","journal-title":"Internal Med (Tokyo Japan)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.884776","article-title":"Immune checkpoint inhibitor-related myositis overlapping with myocarditis: an institutional case series and a systematic review of literature","volume":"13","author":"Nakagomi","year":"2022","journal-title":"Front Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2024-260349","article-title":"Triple M overlap syndrome following pembrolizumab treatment: importance of multidisciplinary approach","volume":"18","author":"G\u00f3mez","year":"2025","journal-title":"BMJ Case Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49867","article-title":"Exploring pembrolizumab-induced myocarditis, myositis, and myasthenia gravis: a comprehensive literature review and case presentation on bladder cancer","volume":"15","author":"Shah","year":"2023","journal-title":"Cureus"},{"key":"B11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.21203\/rs.3.rs-1258443\/v1","article-title":"Management of respiratory failure in immune checkpoint inhibitors-induced overlap syndrome: a case series and review of the literature","volume":"23","author":"Cuenca","year":"2023","journal-title":"BMC Anesthesiology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11625-1","article-title":"Peripheral nervous system adverse events associated with immune checkpoint inhibitors","volume":"270","author":"Rossi","year":"2023","journal-title":"J Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/s0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet (London England)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s004280050044","article-title":"Pathogenesis of myasthenia gravis","volume":"430","author":"Marx","year":"1997","journal-title":"Virchows Archiv Int J Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.594558","article-title":"Sintilimab: a promising anti-tumor PD-1 antibody","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100846","article-title":"A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study","volume":"38","author":"Li","year":"2023","journal-title":"Lancet Regional Health Western Pacific"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115186","article-title":"Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T","volume":"216","author":"Tomsitz","year":"2025","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2254218","article-title":"Immune checkpoint inhibitor-related myocarditis: current understanding and potential diagnostic and therapeutic strategies","volume":"22","author":"Turker","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101478","article-title":"Electrocardiographic features of immune checkpoint inhibitor-associated myocarditis","volume":"48","author":"Song","year":"2023","journal-title":"Curr Problems Cardiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/iju5.12132","article-title":"Editorial comment to pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer","volume":"3","author":"Tomisaki","year":"2019","journal-title":"IJU Case Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2024.07.001","article-title":"Cardiac complications of immune checkpoint inhibitors and chimeric antigen receptor\u2013T cell therapy","volume":"43","author":"Makwana","year":"2025","journal-title":"Cardiol Clinics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195611","article-title":"Immune checkpoint inhibitor-induced myositis\/myocarditis with myasthenia gravis-like misleading presentation: a case series in intensive care unit","volume":"11","author":"Deharo","year":"2022","journal-title":"J Clin Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12134-x","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series","volume":"271","author":"Vicino","year":"2024","journal-title":"J Neurol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2539493","article-title":"Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma","volume":"2019","author":"Fazel","year":"2019","journal-title":"Case Rep Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5050","article-title":"Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: a single-center case series","volume":"12","author":"Longinow","year":"2023","journal-title":"Cancer Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40959-020-00076-6","article-title":"Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series","volume":"6","author":"Arora","year":"2020","journal-title":"Cardio-Oncology (London England)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5126717","article-title":"The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma","volume":"2020","author":"Jeyakumar","year":"2020","journal-title":"Case Rep Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(18)31240-3","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13707","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"42","author":"Wang","year":"2020","journal-title":"Zhonghua Zhong Liu Za Zhi [Chinese J Oncology]"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Internal Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.12.005","article-title":"Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: a meta-analysis","volume":"180","author":"Remon","year":"2023","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","article-title":"Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review","volume":"135","author":"Konstantina","year":"2019","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108554","article-title":"Therapeutic management of patients with advanced thymic Malignancies: a review for clinicians","volume":"204","author":"Pavese","year":"2025","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17611","article-title":"Immunogenicity of neoantigens in colorectal cancer: potential influence of tumor mutation burden, stages, and metastasis","volume":"45","author":"Yu","year":"2025","journal-title":"Anticancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1808170\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:20:46Z","timestamp":1786422046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1808170\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":43,"alternative-id":["10.3389\/fonc.2026.1808170"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1808170","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1808170"}}